Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Target Price at $131.44

Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating) has earned an average rating of “Hold” from the twenty-five analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $131.44.

A number of research firms have commented on ZBH. Needham & Company LLC lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, May 27th. Piper Sandler decreased their price target on shares of Zimmer Biomet from $130.00 to $120.00 in a report on Tuesday, August 2nd. Truist Financial decreased their price target on shares of Zimmer Biomet to $115.00 in a report on Friday, July 22nd. Citigroup boosted their price target on shares of Zimmer Biomet from $114.00 to $119.00 in a report on Wednesday, August 3rd. Finally, Stifel Nicolaus decreased their price target on shares of Zimmer Biomet from $140.00 to $120.00 in a report on Monday, July 18th.

Zimmer Biomet Price Performance

ZBH opened at $114.50 on Thursday. The company has a fifty day moving average price of $109.39 and a two-hundred day moving average price of $115.96. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.95 and a current ratio of 1.81. Zimmer Biomet has a 52 week low of $100.39 and a 52 week high of $153.76. The firm has a market capitalization of $24.02 billion, a PE ratio of 105.05, a P/E/G ratio of 3.29 and a beta of 1.14.

Zimmer Biomet (NYSE:ZBHGet Rating) last released its earnings results on Tuesday, August 2nd. The medical equipment provider reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.19. Zimmer Biomet had a net margin of 3.10% and a return on equity of 12.20%. The firm had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.72 billion. During the same quarter in the previous year, the business earned $1.90 EPS. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, analysts anticipate that Zimmer Biomet will post 6.8 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Shareholders of record on Friday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, September 29th. This represents a $0.96 annualized dividend and a yield of 0.84%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 88.07%.

Insiders Place Their Bets

In other news, insider Zuilen Wilfred Van sold 531 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $105.22, for a total value of $55,871.82. Following the sale, the insider now directly owns 2,240 shares of the company’s stock, valued at approximately $235,692.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.73% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Zimmer Biomet by 19.0% in the 1st quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock valued at $2,954,843,000 after acquiring an additional 3,695,510 shares during the period. BlackRock Inc. raised its holdings in Zimmer Biomet by 0.9% in the 4th quarter. BlackRock Inc. now owns 21,761,864 shares of the medical equipment provider’s stock valued at $2,764,628,000 after acquiring an additional 196,353 shares during the period. JPMorgan Chase & Co. raised its holdings in Zimmer Biomet by 11.5% in the 1st quarter. JPMorgan Chase & Co. now owns 12,772,584 shares of the medical equipment provider’s stock valued at $1,633,612,000 after acquiring an additional 1,321,955 shares during the period. State Street Corp raised its holdings in Zimmer Biomet by 3.3% in the 4th quarter. State Street Corp now owns 9,029,019 shares of the medical equipment provider’s stock valued at $1,149,182,000 after acquiring an additional 290,402 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Zimmer Biomet by 13.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 8,929,342 shares of the medical equipment provider’s stock valued at $938,117,000 after acquiring an additional 1,062,625 shares during the period. 89.39% of the stock is owned by institutional investors.

About Zimmer Biomet

(Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

Read More

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.